Oral Administration of Polymyxin B Modulates the Activity of Lipooligosaccharide E. coli B against Lung Metastases in Murine Tumor Models
Open Access
- 1 February 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148156
Abstract
Polymyxin B (PmB) belongs to the group of cyclic peptide antibiotics, which neutralize the activity of LPS by binding to lipid A. The aim of this study was to analyze the effect of PmB on the biological activity of lipooligosaccharide (LOS E. coli B,rough form of LPS) in vitro and in experimental metastasis models. Cultures of murine macrophage J774A.1 cells and murine bone marrow-derived dendritic cells (BM-DC) stimulated in vitro with LOS and supplemented with PmB demonstrated a decrease in inflammatory cytokine production (IL-6, IL-10, TNF-α) and down-regulation of CD40, CD80, CD86 and MHC class II molecule expression. Additionally, PmB suspended in drinking water was given to the C57BL/6 mice seven or five days prior to the intravenous injection of B16 or LLC cells and intraperitoneal application of LOS. This strategy of PmB administration was continued throughout the duration of the experiments (29 or 21 days). In B16 model, statistically significant decrease in the number of metastases in mice treated with PmB and LOS (pex vivo production of IL-6, IL-1β and TNF-α by peritoneal cells were observed 7 days earlier. By contrast, antigen expression and ex vivo production of IL-6, IL-10, IFN-γ by splenocytes remained relatively high and stable. Statistically significant decrease in LLC metastases number was observed after the application of LOS (pin vivo application of PmB was not able to neutralize the LOS-induced immune cell activity but its presence in the organism of treated mice was important in modulation of the LOS-mediated response against the development of metastases.Keywords
This publication has 29 references indexed in Scilit:
- T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator ProductionPLOS ONE, 2013
- Polymyxins as Novel and Safe Mucosal Adjuvants to Induce Humoral Immune Responses in MicePLOS ONE, 2013
- Lipopolysaccharide-Activated Dendritic Cells: “Exhausted” or Alert and Waiting?The Journal of Immunology, 2012
- Effective use of polymyxin B hemoperfusion in septic shock complicated by urosepsisIndian Journal of Nephrology, 2011
- Two physically, functionally, and developmentally distinct peritoneal macrophage subsetsProceedings of the National Academy of Sciences, 2010
- Interactions of Lipopolysaccharide and Polymyxin Studied by NMR SpectroscopyJournal of Biological Chemistry, 2009
- Phenotypic non‐equivalence of murine (monocyte‐) macrophage cells in biomaterial and inflammatory modelsJournal of Biomedical Materials Research Part A, 2008
- Modification of the Structure of Peptidoglycan Is a Strategy To Avoid Detection by Nucleotide-Binding Oligomerization Domain Protein 1Infection and Immunity, 2007
- Lipopolysaccharide EndotoxinsAnnual Review of Biochemistry, 2002
- A New Method for the Extraction of R LipopolysaccharidesEuropean Journal of Biochemistry, 1969